First author, (Year) | Country | Study design | Study population | Sample size | Intervention group | Control group | Duration | Microbiota analysis method | Changes on microbiota or metabolites derive | Clinical outcomes |
---|---|---|---|---|---|---|---|---|---|---|
Ferraris C., et al. (2021) [12] | Italy | Single-arm, uncontrolled, quasi experimental | Patients with epilepsy Age: 2-46 yr Male:3 Female:4 | N = 7 | N = 7 | N.A | One month | Cytotoxicity, genotoxicity, measuring SCFA | Decrease in fecal SCFA, (acetate, propionate, butyrate), isobutyrate | Decrease in seizures attacks (> 50%) and involuntary movements |
Bahr L., et al. (2018) [22] | Germany | Single-center, randomized, controlled, parallel-group study | Patients with relapsing–remitting MS Age: 18-65 yr Male: N.A Female: N.A | N = 111 (37 patients in each KD, FD and SD groups) | N = 74 (37 patients in KD group and 37 patients in FD group) | N = 37 | Nine months | Biochemical measures | Increase in serum beta hydroxybutyrate level | Improve cognition in KD group |
Lee R., et al. (2018) [14] | United States | Open-label, observer-blinded, quasi experimental | children with ASD Mean age: 7.9 ± 3.3 yr Male:13 Female:2 | N = 15 | N = 15 | N.A | Three months | Biochemical measures | Increase in serum beta hydroxybutyrate level | Improve behaviors |
Swidsinski A., et al. (2017) [15] | Germany | Controlled, randomized clinical trials | Patients with MS Mean age: N.A Male: N.A Female: N.A | N = 24 (10 patients in KD and 14 patients in control group) | N = 10 | N = 14 | Six months | FISH with ribosomal RNA derived probs | Decrease in pioneer bacterial groups, increase in Akkermansia | Positive effects on MS patients |
Xie G., et al. (2017) [16] | China | Controlled, randomized clinical trials | Children with epilepsy Mean age: 1.95 ± 3.1 yr Male: 11 Female: 3 | N = 44 (14 patients in KD group and 30 healthy infants in control group) | N = 14 | N = 30 | One week | 16 s rRNA sequencing | Decrease in Proteobacteria Cronobacter, no change in Bacteroides, increase in Prevotella, Bifidobacterium | Clinical improvement (64%), decrease in seizure frequency (50%) |
Tagliabue A., et al. (2016) [17] | Italy | Prospective, single-center, single-arm quasi experimental | Epileptic patients affected by GLUT1 DS Age: 8-34 yr Male:3 Female:3 | N = 6 | N = 6 | N.A | Three months | RT-PCR and bacterial DNA extraction | Increase in Desulfovibrio spp. | No change |